Table 4. Effect of GCV treatment on... | American Society of Hematology

Table 4.

Effect of GCV treatment on circulating GMCs

Patient no.	GCV treatment		GMCs among circulating lymphocytes, %			Circulating GMCs, × 10⁶/L
Patient no.	Diagnosis	Initiation date	Pre-GCV	Post-GCV (d)	Reduction	Pre-GCV	Post-GCV	Reduction
1	Acute GVHD	D31	0.54^4-150	0.01^4-150 (D47)	98.1	NA	NA	NA
9	Chronic GVHD	D134	0.1	0.015 (D146)	85	0.46	0.09	80.4
11	Acute GVHD	D238^4-151	1.28	0.083 (D245)	93.5	4.14	0.01	99.7
12	Acute GVHD + CMV infection	D40	14.86	0.82 (D56)	94.5	28.2	6.83	75.8

Patient no.	GCV treatment		GMCs among circulating lymphocytes, %			Circulating GMCs, × 10⁶/L
Patient no.	Diagnosis	Initiation date	Pre-GCV	Post-GCV (d)	Reduction	Pre-GCV	Post-GCV	Reduction
1	Acute GVHD	D31	0.54^4-150	0.01^4-150 (D47)	98.1	NA	NA	NA
9	Chronic GVHD	D134	0.1	0.015 (D146)	85	0.46	0.09	80.4
11	Acute GVHD	D238^4-151	1.28	0.083 (D245)	93.5	4.14	0.01	99.7
12	Acute GVHD + CMV infection	D40	14.86	0.82 (D56)	94.5	28.2	6.83	75.8

Quantitative PCR was not performed in the 2 other patients treated by GCV (patient no. 3, acute GVHD day 15; patient no. 6, acute GVHD day 20). However, semiquantitative PCR confirmed the presence of circulating GMCs at diagnosis of GVHD in both patients (at a very low level for patient no. 6) and a significant decrease of GMCs associated with GCV treatment. NA indicates not available.

F4-150

Indicates the percentage of GMCs among cells after Ficoll gradient separation.

F4-151

Indicates the refractory lethal GVHD after (unmanipulated) donor lymphocyte infusion.

View Large

This Feature Is Available To Subscribers Only